Introduction
Myeloproliferative neoplasms (MPN) are a group of chronic blood disorders in which the bone marrow produces too many blood cells. Depending on the subtype, the body may produce excess red blood cells, white blood cells, or platelets. Over time, MPNs can increase the risk of blood clots, bleeding, enlarged spleen, and in some cases progression to bone marrow scarring (myelofibrosis) or acute leukemia.
MPNs are usually long-term conditions that require accurate diagnosis, risk assessment, and ongoing monitoring. With modern hematology care, many patients achieve good disease control and maintain a high quality of life.
Türkiye is a trusted destination for advanced hematology services, offering experienced specialists, modern molecular diagnostics, and access to evidence-based therapies for MPNs.
Averia Health supports international patients through ethical, structured, and fully coordinated MPN care focused on accurate classification, prevention of complications, and long-term treatment continuity.
Why Choose Türkiye for MPN Treatment
Türkiye is internationally recognized for high-quality hematology care because of:
- Experienced hematologists specialized in chronic blood disorders
- Advanced molecular testing (JAK2, CALR, MPL mutations)
- Modern diagnostic pathology and bone marrow services
- Structured thrombosis prevention and monitoring protocols
- Access to targeted therapies and supportive care
- Internationally accredited hospitals
Türkiye combines clinical expertise with comprehensive long-term hematology care.
Why Choose Averia Health
Averia Health provides complete coordination for myeloproliferative neoplasm evaluation and treatment:
- Pre-arrival review of blood counts and prior hematology reports
- Referral to experienced MPN specialists
- Coordination of diagnostic testing and bone marrow evaluation
- Clear explanation of MPN subtype and risk category
- Personalized treatment planning and monitoring schedule
- Interpreter services for full clarity
- 24/7 patient support during your stay
- International follow-up coordination and long-term care planning
Our approach prioritizes safety, transparency, and prevention of complications.
Types of Myeloproliferative Neoplasms (MPN)
MPNs include several major subtypes:
Polycythemia Vera (PV)
- Overproduction of red blood cells
- Increased blood thickness and clot risk
Essential Thrombocythemia (ET)
- Overproduction of platelets
- Increased risk of clotting or bleeding depending on platelet function
Primary Myelofibrosis (PMF)
- Bone marrow scarring leading to reduced healthy blood cell production
- Often associated with spleen enlargement and systemic symptoms
Other less common MPNs may also be evaluated by hematology specialists.
Symptoms of MPN
Symptoms vary by subtype and severity. Patients may experience:
- Headaches, dizziness, or visual disturbances
- Fatigue and weakness
- Itching (especially after warm shower)
- Flushing or burning sensation in hands/feet
- Unexplained weight loss
- Night sweats
- Abdominal fullness (enlarged spleen)
- Easy bruising or bleeding
- Blood clots (DVT, PE, stroke) in some patients
Some MPN cases are detected through routine blood tests without symptoms.
Diagnostic Evaluation for MPN
Accurate diagnosis and classification may include:
- Complete blood count (CBC) and peripheral smear
- Blood chemistry tests
- Iron studies and inflammation markers
- Molecular testing:
- JAK2 mutation testing
- CALR mutation testing
- MPL mutation testing
- Bone marrow aspiration and biopsy
- Cytogenetic testing (selected cases)
- Imaging for spleen size assessment (ultrasound or CT)
Testing confirms the diagnosis and supports risk-based treatment planning.
Treatment Options for MPN
Treatment depends on MPN subtype, symptoms, age, and clotting risk.
Thrombosis Prevention
- Low-dose antiplatelet therapy in selected patients
- Anticoagulation in patients with prior blood clots
- Management of cardiovascular risk factors (blood pressure, cholesterol, smoking)
Cytoreductive Therapy (Reducing Blood Cell Counts)
- Medications to lower red blood cell or platelet levels
- Used for higher-risk patients or those with symptoms/complications
Phlebotomy (For Polycythemia Vera)
- Controlled blood removal to reduce hematocrit
- Often combined with medication and risk management
Targeted Therapy (Selected Cases)
- Targeted medications may be used depending on mutation status and disease severity
Supportive Care
- Treatment for itching, fatigue, or anemia
- Monitoring for spleen enlargement and disease progression
Treatment is individualized and aims to prevent complications and maintain quality of life.
Treatment Journey in Türkiye
- Pre-Arrival Case Review
Blood tests and prior reports are reviewed in advance. - Hematology Specialist Consultation
Symptoms, risks, and diagnostic needs are assessed. - Diagnostic Confirmation
Molecular testing and bone marrow biopsy are arranged if needed. - Risk Stratification & Treatment Planning
MPN subtype and complication risk are explained clearly. - Treatment and Monitoring
Therapy begins with structured follow-up of blood counts and symptoms. - International Continuity of Care
Long-term monitoring plans and follow-up guidance are coordinated for home-country care.
Expected Results & Benefits
- Accurate diagnosis and subtype classification
- Reduced risk of blood clots and complications
- Better symptom control (fatigue, itching, spleen discomfort)
- Stabilized blood counts through personalized therapy
- Clear long-term monitoring strategy
Many MPN patients achieve stable long-term disease control with appropriate care.
Risks & Considerations
MPN management requires careful monitoring. Considerations include:
- Increased clotting risk if not properly controlled
- Bleeding risk in selected patients
- Medication side effects depending on therapy type
- Need for long-term follow-up and blood count monitoring
- Potential disease progression in some cases
All treatment decisions are discussed transparently and ethically.
What’s Included in Your Medical Trip
- Hematology consultation
- Review of prior laboratory results and reports
- Advanced molecular testing coordination
- Bone marrow biopsy coordination (if indicated)
- Personalized treatment plan and risk prevention strategy
- Medications and supportive care coordination
- Interpreter services
- 24/7 patient support
- Medical reporting and international follow-up coordination
Averia Health ensures ethical, structured, and patient-centered MPN care.
Frequently Asked Questions
Are MPNs cancer?
MPNs are classified as blood cancers, but many behave as chronic diseases and can be managed long-term.
Do all MPN patients need treatment?
Not always. Some patients require monitoring only, while others need medication to reduce risk and control symptoms.
Can MPN cause blood clots?
Yes. Preventing thrombosis is a key part of MPN management.
Is bone marrow biopsy necessary?
Often yes, especially for confirming subtype and evaluating disease stage.
Can international patients continue follow-up after returning home?
Yes. We provide medical summaries and long-term monitoring guidance.
Ready to Start Your Health Journey?
Get expert diagnosis and personalized treatment for myeloproliferative neoplasms (MPN) in Türkiye with advanced hematology care and full international coordination.
Request a free quote or contact us on WhatsApp to speak with our international care coordination team.
